Feldene’s discontinuation likely stems from a combination of factors. Decreased profitability, due to the availability of newer, safer NSAIDs, played a significant role. Manufacturing costs may have also increased, impacting its viability.
Safety concerns also contributed. While effective, piroxicam (Feldene’s active ingredient) carries a risk of serious gastrointestinal complications, such as ulcers and bleeding. This increased liability and the potential for lawsuits likely influenced the decision.
Generic alternatives are readily available, offering comparable pain relief at lower costs. This market shift reduced demand for the brand-name medication, further contributing to its withdrawal.
Regulatory changes also play a part. Stringent regulatory requirements and ongoing safety reviews could increase manufacturing and compliance costs, making the drug less profitable.
Patients previously prescribed Feldene should consult their doctor to discuss suitable alternatives. Numerous NSAIDs and other pain management options exist. Your physician can help find a safe and effective replacement tailored to your individual needs and health history.
